Personalized peptide vaccination: A novel immunotherapeutic approach for advanced cancer

Figures & data

Figure 1. Personalized vaccines are more promising than common vaccines. Personalized antigens can induce quick and strong secondary immune responses, whereas common antigens without immunological memory induce slow and weak primary immune responses.

Table 1. Clinical responses of advanced cancer patients treated with PPV

	Patient (n)	Evaluable patient (n)		Best clinical response (n)				Response rate (%)	Disease control rate (%)
				PR	SD	PD
Total	500	436		43	144	249		9.9	42.9
Prostatic	174	155		29	36	90		18.7	41.9
Colorectal	74	68		1	23	44		1.5	35.3
Pancreatic	50	41		4	23	14		9.8	65.9
Gastric	42	35		0	8	27		0	22.9
Brain	33	30		5	11	14		16.7	53.3
Cervical	28	23		3	7	13		13.0	43.5
Non-small cell lung	22	21		0	11	10		0	52.4
Renal cell	13	12		0	9	3		0	75.0
Melanoma	12	11		0	5	6		0	45.5
Breast	11	10		0	1	9		0	10.0
Uroepithelial	10	7		1	2	4		14.3	42.9
Others	31	23		0	8	15		0	34.8

Best clinical responses were evaluated by RECIST criteria (or PSA values in prostatic cancer). PR, partial response; SD, stable disease; PD, progressive disease

Figure 2. Progression-free and overall survival in patients with castration-resistant prostate cancer using personalized peptide vaccination. Kaplan-Meier curves of progression-free (A) and overall survival (B) in patients treated with personalized peptide vaccination plus low-dose estramustine phosphate (EMP) or standard-dose EMP. Adapted from Noguchi et al.¹⁸

Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59:1001 - 9; http://dx.doi.org/10.1007/s00262-010-0822-4; PMID: 20146063

 PubMed Web of Science ®Google Scholar